Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (GVHD)
AssigneeGentium S.R.L.
InventorMassimo Iacobelli
Life of this patent
Estimating the term…
Abstract
Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.
Claims18
A method of preventing or alleviating graft-versus-host disease (GVHD) comprising identifying a patient at risk of developing GVHD and administering an amount of defibrotide sufficient to reduce the occurrence or severity of GVHD to the patient before the patient is subjected to hematopoietic stem cell transplantation (HSCT).
Dependencies are inferred from the claim text.